中文
Earlier issues
Announcement
More
Progress in Chemistry 2014, Vol. 26 Issue (06): 1039-1049 DOI: 10.7536/PC131127 Previous Articles   Next Articles

• Review •

Targeted Drug Delivery Systems Based on Cyclodextrins

Han Bin, Liao Xiali*, Yang Bo*   

  1. Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China
  • Received: Revised: Online: Published:
  • Supported by:

    The work was supported by the National Natural Science Foundation of China(No. 21062009, 21362016) and Yunnan Natural Science Foundation Project(No. 2011FZ059)

PDF ( 2521 ) Cited
Export

EndNote

Ris

BibTeX

Targeted drug delivery system (TDDS) nowadays has been adopted as a superb approach to the therapies of cancer and other mortal diseases. Cyclodextrins (CDs) are chosen to take the part of a promising drug carrier due to its low toxicity and high flexibility of structure modification. They are commonly used to enhance the aqueous solubility, chemical stability, safety and bioavailability of drugs in virtue of their peculiar ability to form CD/drug inclusion complexes. Not only native and chemically modified cyclodextrins were employed as drug carriers, but also sorts of CD-based more sophisticated carrier systems such as polyrotaxanes/polypseudorotaxanes, polycations and nanoparticles emerged in recent years. Considering the fact that lots of biological receptors such as folate receptor, asialoglycoprotein receptor, hyaluronic receptor, transferrin receptor, integrin receptor are overexpressed on the surface of most cancer cells and other focal cells, design of TDDS containing matching targeting ligands (TLs) could help realize targeted therapy for those focal cells or tissues. Targeting ligands such as folic acid (FA), mono- and oligosaccharides, hyaluronic acid (HA), transferrin, RGD sequence are consequently chemically bound to CD-based carriers to form targeted carrier systems which further furnished TDDS via non-covalent complexation or bio-cleavable conjugation to drug molecules. Such TDDS are also widely applied on nucleic acid delivery in addition to chemotherapeutical drugs. As to depict the important developments, basic targeting principles and the latest progress on targeted drug delivery systems based on CDs are summarized, and also a brief prospect is given in this review.

Contents
1 Introduction
2 Folate receptor-mediated TDDS based on CDs
2.1 Targeting mechanism
2.2 Progress on folate receptor-mediated TDDS based on CDs
3 Asialoglycoprotein receptor-mediated TDDS based on CDs
3.1 Targeting mechanism
3.2 Progress on asialoglycoprotein receptor-mediated TDDS based on CDs
4 Hyaluronic receptor-mediated TDDS based on CDs
4.1 Targeting mechanism
4.2 Progress on hyaluronic receptor-mediated TDDS based on CDs
5 Transferrin receptor-mediated TDDS based on CDs
5.1 Targeting mechanism
5.2 Progress on transferrin receptor-mediated TDDS based on CDs
6 Integrin receptor-mediated TDDS based on CDs
6.1 Targeting mechanism
6.2 Progress on integrin receptor-mediated TDDS based on CDs
7 Other receptor-mediated TDDS based on CDs
8 Conclusion

Key words: cyclodextrin, targeted drug delivery system (TDDS), receptor, targeting ligand

CLC Number: 

[1] Yague E, Raguz S. Brit. J. Cancer, 2005, 93: 973.
[2] Tan S Y, Grimes S. Singap. Med. J., 2010, 51: 842.
[3] 闫真芳(Yan Z F), 徐希明(Xu X M), 余江男(Yu J N). 药物生物技术(Pharmaceutical Biotechnology), 2009, 16: 481.
[4] 陈湧(Chen Y), 刘育(Liu Y). 有机化学(Chinese Journal of Organic Chemistry), 2012, 32: 805.
[5] Wang J, Cao Y P, Sun B G, Wang C T. Food Chem., 2011, 127: 1680.
[6] 孙涛(Sun T), 李建业(Li J Y), 郝爱友(Hao A Y). 有机化学(Chinese Journal Organic Chemistry), 2012, 32: 2054.
[7] Loftsson T, Duchene D. Int. J. Pharm., 2007, 329: 1.
[8] Szejtli J. Chem. Rev., 1998, 98: 1743.
[9] Freudenberg K, Cramer F, Plieninger H. DE 895769, 1953.
[10] Chen Y, Liu Y. Chem. Soc. Rev., 2010, 39: 495.
[11] D’Souza V T, Bender M L. Acc. Chem. Res., 1987, 20: 146.
[12] Bilensoy E. Cyclodextrins in Pharmaceutics, Cosmetics, and Biomedicine: Current and Future Industrial Applications. New Jersey: John Wiley, 2011.
[13] Chordiya M A, Senthilkumaran K. J. Pharm. Pharmacol., 2012, 1: 19.
[14] Hwang S J, Bellocq N C, Davis M E. Bioconju. Chem., 2001, 12: 280.
[15] Flourie B, Molis C, Achour L, Dupas H, Hatat C, Rambaud C J. J. Nutr., 1993, 123: 676.
[16] Garcia-Lopez J J, Hemandez-Mateo F, Isac-Garcia L, Kim J M, Roy R, Santoyo-Gonzalez F, Vargas-Berenguel A. J. Org. Chem., 1999, 64: 522.
[17] Hirayama F, Minami K, Uekama K. J. Pharm. Pharmacol., 1996, 48: 27.
[18] Uekama K, Minami K, Hirayama F. J. Med. Chem., 1997, 40: 2755.
[19] El-Kamel A H, Abdel-Aziz A A M, Fatani A J, El-Subbagh H I. Int. J. Pharm., 2008, 358: 248.
[20] Leamon C P, Reddy J A. Adv. Drug. Deliv. Rev., 2004, 56: 1127.
[21] Sabharanjak S, Mayor S. Adv. Drug. Deliv. Rev., 2004, 56: 1099.
[22] Chen C, Ke J Y, Zhou E X, Yi W, Brunzelle J S, Li J, Yong E L, Xu E H, Melcher K. Nature, 2013, 500: 486.
[23] 张莉(Zhang L), 潘俊(Pan J), 陆伟跃(Lu Y W). 国外医药:合成药、生化药、制剂分册(World Pharmacy),2002, 23(6): 359.
[24] Sudimack J, Lee R J. Adv. Drug. Deliv. Rev., 2000, 41: 147.
[25] Leamon C P, Deprince R B, Hendren R W. Drug Target, 1999, 7: 157.
[26] Leamon C P, Cooper S R, Hardee G E. Bioconju. Chem., 2003, 14: 738.
[27] Clementi A, Aversa M C, Corsaro C, Spooren J, Stancanelli R, O’Connor C, McNamara M, Mazzaglia A. J. Incl. Phenom. Macrocycl. Chem., 2011, 69: 321.
[28] Salmaso S, Semenzato A, Caliceti P, Hoebeke J, Sonvico F, Dubernet C, Couvreur P. Bioconju. Chem., 2004, 15: 997.
[29] Yin J J, Sharma S, Shumyak S P, Wang Z X, Zhou Z W, Zhang Y D, Guo P X, Li C Z, Kanwar J R, Yang T X, Mohapatra S S, Liu W Q, Duan W, Wang J C, Li Q, Zhang X J, Tan J, Jia L, Liang J, Wei M Q, Li X T, Zhou S F. PLoS One, 2013, 8: e62289.
[30] Yang Y, Zhang Y M, Chen Y, Zhao D, Chen J T, Liu Y. Chem. Eur. J., 2012, 18: 4208.
[31] 刘育(Liu Y), 杨洋(Yang Y), 张瀛溟(Zhang Y M). CN 102258788B, 2012.
[32] 赖春丽(Lai C L), 赖乐(Lai L), 赵建彬(Zhao J B), 陈建海(Chen J H). 药学学报(Acta Pharmaceutica Sinica), 2010, 45: 920.
[33] Zhou Y, Wang H, Wang C X, Li Y S, Lu W F, Chen S F, Luo J D, Jiang Y N, Chen J H. Mol. Pharm., 2012, 9: 1067.
[34] Zhao F, Yin H, Zhang Z X, Li J. Biomacromolecules, 2013, 14: 476.
[35] Okamatsu A, Motoyama K, Onodera R, Higashi T, Koshigoe T, Shimada Y, Hattori K, Takeuchi T, Arima H. Bioconju. Chem., 2013, 24: 724.
[36] Fallon R J, Schwartz A L. Adv. Drug. Deliv. Rev., 1989, 4: 49.
[37] Donati I, Gamini A, Vetere A, Campa C, Paoletti S. Biomacromolecules, 2002, 3: 805.
[38] Wu J, Nantz M H, Zern M A. Front. Biosci., 2002, 7: d717.
[39] Stockert R J. Physiol. Rev., 1995, 75: 591.
[40] 吴卫(Wu W), 程怡(Cheng Y), 吴琼(Wu Q). 南京医科大学学报(Acta Universitatis Medicinalis Nanjing), 2012, 32:168.
[41] Hattori K, Kenmoku, Mizuguchi T, Ikeda D, Mizuno M, Inazu T. J. Incl. Phenom. Macrocycl. Chem., 2006, 56: 9.
[42] Yasuda N, Aoki N, Abe H, Hattori K. Chem. Lett., 2000, 3: 706.
[43] Pun S H, Bellocq N C, Liu A J, Jensen G, Machemer T, Quijano E, Schluep T, Wen S F, Engler H, Heidel J, Davis M E. Bioconju. Chem., 2004, 15: 831.
[44] 雒琪(Luo Q), 钱皓(Qian H), 王凤山(Wang F S). 中国生化药物杂志(Chinese Journal of Biochemical Pharmaceutics), 2008, 29: 359.
[45] Aruffo A, Stamenkovic I, Melnick M, Underhill C B, Seed B. Cell, 1990, 61: 1303.
[46] Naor D, Sionov R V, Ish-Shalom D. Adv. Cancer Res., 1997, 71: 241.
[47] Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. Crit. Rev. Clin. Lab. Sci., 2002, 39: 527.
[48] Peach R J, Hollenbaygh D, Stamenkovic I, Aruffo A. J. Cell. Biol., 1993, 122: 257.
[49] Oh E J, Park K, Kin K S, Kim J, Yang J A, Kong J H, Lee M Y, Hoffman A S, Hahn S K. J. Control. Release, 2010, 141: 2.
[50] Luo Y, Prestwich G D. Biocunju. Chem., 1999, 10: 755.
[51] Luo Y, Ziebell M R, Prestwich G D. Biomacromolecules, 2000, 1: 208.
[52] Banzato A, Bobisse S, Rondina M, Renier D, Bettella F, Esposito G, Quintieri L, Meléndez-Alafort L, Mazzi U, Zanovello P, Rosato A. Clin. Cancer Res., 2008, 14: 3598.
[53] Galer C E, Sano D S, Ghosh S C, Hah J H, Auzenne E, Hamir A N, Myers J N, Klostergaard J. Oral Oncol., 2011, 47: 1039.
[54] Li J, Huang P, Chang L, Long X, Dong A, Liu J, Chu L, Hu F, Liu J, Deng L. Macromol. Res., 2013, 21, 1331.
[55] Montagner I M, Banzato A, Zuccolotto G, Renier D, Campisi M, Bassi P F, Zanovello P, Rosato A. Urol. Oncol. Semin. Ori., 2013, 31: 1261.
[56] Tsai S W, Yu D S, Tsao S W, Hsu F Y. Int. J. Nanomed., 2012, 8: 2399.
[57] Li S D, Howell S B. Mol. Pharm., 2010, 7: 280.
[58] Tsai S W, Yu D S, Tsao S W, Hsu F Y. Int. J. Nanomed., 2013, 8: 2399.
[59] Dong Z, Zheng W, Xu Z, Yin Z. J. Appl. Polym. Sci., 2013, 130: 927.
[60] Yang X, Dogan I, Pannala V R, Kootala S, Hilborn J, Ossipov D. Polym. Chem., 2013, 4: 4621.
[61] Di Meo D, Panza L, Capitani D, Mannina L, Banzato A, Rondina M, Renier D, Rosato A, Crescenzi V. Biomacromolecules, 2007, 8: 552.
[62] Charlot A, Heyraud A, Guenot P, Rinaudo M, Auzély-Velty R. Biomacromolecules, 2006, 7: 907.
[63] Charlot A, Auzély-Velty R. Macromolecules, 2007, 40: 9555.
[64] Yang Y, Zhang Y M, Chen Y, Chen J T, Liu Y. J. Med. Chem., 2013, 56: 9725.
[65] 刘育(Liu Y), 杨洋(Yang Y), 张瀛溟(Zhang Y M). CN 102698286A, 2012.
[66] 杨媛(Yang Y), 娄琨(Lou K), 梅兴国(Mei X G), 吕万良(Lv W L). 中国药学杂志(Chinese Pharmaceutical Journal), 2009, 44: 1761.
[67] 蒋新国(Jiang X G). 复旦学报(医学版)(Fudan University Journal of Medical Sciences), 2012, 39: 441.
[68] 姜嫣嫣(Jiang Y Y), 裴元英(Pei Y Y). 第六届中国药学会学术年会论文集(Proceeding of the 6th Annual Conference of Chinese Pharmaceutical Association). 北京: 中国药学会(Beijing: Chinese Pharmaceutical Association), 2006. 3797.
[69] Simes S, Slepushkin V, Gaspar R, de Lima M C P, Düzgüne N. Gene Therapy, 1998, 5: 955.
[70] Ishida O, Maruyama K, Tanahashi H, Iwatsuru M, Sasaki K, Eriguchi M, Yanagie H. Pharmaceut. Res., 2001, 18: 1042.
[71] Kursa M, Walker G F, Roesler V, Ogris M, Roedl W, Kircheis R, Wagner E. Bioconju. Chem., 2003, 14: 222.
[72] 叶树楠(Ye S N), 杨述华(Yang S H), 吴强(Wu Q),杨操(Yang C), 李进(Li J), 许伟华(Xu W H). 肿瘤(Tumor), 2005, 25: 321.
[73] Suzuki R, Takizawa T, Kuwata Y, Mutoh M, Ishiguro N, Utoguchi N, Shinohara A, Eriguchi M, Yanagie H, Maruyama K. Int. J. Pharm., 2008, 346: 143.
[74] Hong M, Zhu S, Jiang Y, Tang G, Pei Y. J. Control. Release, 2009, 133: 96.
[75] Hong M, Zhu S, Jiang Y, Tang G, Sun C, Fang C, Shi B, Pei Y. J. Control. Release, 2010, 141: 22.
[76] Nie Y, Schaffert D, Rdl W, Ogris M, Wagner E, Günther M. J. Control. Release, 2011, 152: 127.
[77] Li Y, He H, Jia X, Lu W L, Lou J, Wei Y. Biomaterials, 2012, 33: 3899.
[78] Tros de Ilarduya C, Düezgüene ??塂 N. Expert Opin. Drug Del., 2013, 10: 1583.
[79] Davis M E. Mol. Pharm., 2009, 6: 659.
[80] Heidel J D, Yu Z, Liu J Y, Rele S M, Liang Y, Zeidan R K, Kornbrust D J, Davis M E. Proc. Natl. Acad. Sci. U.S.A., 2007, 104: 5715.
[81] Bartlett D W, Davis M E. Bioconju. Chem., 2007, 18: 456.
[82] Hu-Lieskovan S, Heidel J D, Bartlett D W, Davis M E, Triche T J. Cancer Res., 2005, 65: 8984.
[83] Bellocq N C, Pun S H, Jensen G S, Davis M E. Bioconju. Chem., 2003, 14: 1122.
[84] Pun S H, Tack F, Bellocq N C, Cheng J, Grubbs B H, Jensen G S, Davis M E, Brewster M, Janicot M, Janssens B, Floren W, Bakker A. Canc. Biol. Ther., 2004, 3: 641.
[85] Brahmamdam P, Watanabe E, Unsinger J, Chang K C, Schierding W, Hoekzema A S, Zhou T T, McDonough J S, Holemon H, Heidel J D, Coopersmith C M, McDunn J E, Hotchkiss R S. Shock, 2009, 32: 131.
[86] 安莲效(An L X), 李慧(Li H), 顾月清(Gu Y Q). 中国生化药物杂志(Chinese Journal of Biochemical Pharmaceutics), 2010, 31: 66.
[87] Garanger E, Boturyn D, Dumy P. Anticancer Agents Med. Chem., 2007, 7: 552.
[88] Quan C Y, Chen J X, Wang H Y, Li C, Chang C, Zhang X Z, Zhuo R X. J. Am. Chem. Soc., 2010, 4: 4211.
[89] Tran N Q, Joung Y K, Lih E, Park K M, Park K D. Macromol. Res., 2011, 19: 300.
[90] Miao Q H, Li S P, Han S Y, Wang Z, Wu Y, Nie G J. J. Nanopart. Res., 2012, 14: 1043.
[91] Seo J H, Kakinoki S, Inoue Y, Yamaoka T, Ishihara K, Yui N. J. Am. Chem. Soc., 2013, 135: 5513.
[92] 吴镁春(Wu M C), 王驰(Wang C). 中国新药杂志(Chinese Journal of New Drugs), 2010, 19: 569.
[93] Paliwal S R, Paliwal R, Agarawal G P, Vyas S P. Crit. Rev. Ther. Drug. Carr. Sys., 2012, 29: 421.
[94] Maruta F, Parker A L, Fisher K D, Hallissey M T, Ismail T, Rowlands D C, Chandler L A, Kerr D J, Seymour L W. Cancer Gene Ther., 2002, 9: 543.
[95] Ng K K, Lovell J F, Zheng G. Acc. Chem. Res., 2011, 44: 1105.
[96] Kader A, Pater A. J. Control. Release, 2002, 80: 29.
[97] Shukla J, Sharma U, Kar R, Varma I K, Juyal S, Jagannathan N R, Bandopadhyaya G P. Nanomedicine, 2009, 4: 895.
[98] Hu Y P, Tang G P, Liu J, Cheng W X, Yue Y, Li J C, Zhang P. J. Biomed. Biotechnol., 2012, 989235.
[1] Ren Zhihua, Yang Xiaoxi, Sun Zhendong, Ren Jing, Sang Nan, Zhou Qunfang, Jiang Guibin. Regulation of Environmental Endocrine Disrupting Chemicals on the Expressions and Transactivation of Estrogen Receptors and the Related Analytical Techniques [J]. Progress in Chemistry, 2022, 34(10): 2121-2133.
[2] Xiaohan Hou, Shengnan Liu, Qingzhi Gao. Application of Small-Molecule Fluorescent Probes in the Development of Green Pesticides [J]. Progress in Chemistry, 2021, 33(6): 1035-1043.
[3] Yunxue Xu, Renfu Liu, Kun xu, Zhifei Dai. Fluorescent Probes for Intraoperative Navigation [J]. Progress in Chemistry, 2021, 33(1): 52-65.
[4] Xia Li, Hongyan Ma, Xiaojuan Nie, Xu Liu, Chengming Bian, Long Xie. Preparation of Star-Like Polymer Based on Cyclodextrin and Its Application [J]. Progress in Chemistry, 2020, 32(7): 935-942.
[5] Mingfang Ma, Tianxiang Luan, Pengyao Xing, Zhaolou Li, Xiaoxiao Chu, Aiyou Hao. Low Molecular Weight Organic Compound Gel Based on β-cyclodextrin [J]. Progress in Chemistry, 2019, 31(2/3): 225-235.
[6] Benzhan Zhu, Chen Shen, Zhiguo Sheng. Mechanism of the Endocrine-Disruptive Effects of Low-Dose Bisphenol A via Transmembrane Receptor [J]. Progress in Chemistry, 2019, 31(1): 167-179.
[7] Qian Zhao, Shenghua Li, Yu Liu*. Construction and Functions of Supramolecular Cyclodextrin Gels [J]. Progress in Chemistry, 2018, 30(5): 673-683.
[8] Wu Hongwei, Chen Yayun, Rao Caihui, Liu Chuanxiang*. Anion Receptors Based on CH Donor Group [J]. Progress in Chemistry, 2016, 28(10): 1501-1514.
[9] Shen Haimin, Wu Hongke, Shi Hongxin, Ji Hongbing, Yu Wubin. Application of the Heterogeneous Cyclodextrins in Aqueous Phase Organic Synthesis [J]. Progress in Chemistry, 2015, 27(1): 70-78.
[10] Liao Rongqiang, Liu Manshuo, Liao Xiali, Yang Bo. Cyclodextrin-Based Smart Stimuli-Responsive Drug Carriers [J]. Progress in Chemistry, 2015, 27(1): 79-90.
[11] Xu Niwei, Liu Mengyan, Hong Shibin, Yan Wei, Fu Jifang, Deng Wei. Recent Progress in Gene Delivery Based on Cyclodextrin [J]. Progress in Chemistry, 2014, 26(0203): 375-384.
[12] Xiong Yuting, Li Minmin, Xiong Peng, Yang Meng, Qing Guangyan, Sun Taolei. Artificial Carbohydrate Receptors in Aqueous Media [J]. Progress in Chemistry, 2014, 26(01): 48-60.
[13] Peng Liao, Feng Anchao, Wang Hong, Zhang Huijuan, Yuan Jinying. Voltage-Responsive Systems Based on β-Cyclodextrin and Ferrocene [J]. Progress in Chemistry, 2013, 25(11): 1942-1950.
[14] Michael B. Sporn, Karen T. Liby. A Mini-Review of Chemoprevention of Cancer——Past, Present, and Future [J]. Progress in Chemistry, 2013, 25(09): 1421-1428.
[15] Barbara K. Dunn. Phase 3 Trials in Breast Cancer Prevention：Focus on Estrogen-Targeting Agents, Selective Estrogen Receptor Modulators and Aromatase Inhibitors [J]. Progress in Chemistry, 2013, 25(09): 1429-1449.